POXEL : SP 09/05/24 : Avis de scission de la société...

Raoul32

12 mai 2024 •13:58

Je ne suis pas sur d'avoir compris,  quelqu'un pourrait développer 

BCF64

12 mai 2024 •14:01

Sumitomo Pharma Co., Ltd. (the "Company") passed a resolution at its Board of Directors meeting held on May 9, 2024 to implement the company split of its Frontier Business and transfer to FrontAct Co., Ltd. ("FrontAct"), a wholly-owned subsidiary of the Company established on April 1, 2024, (the "Absorption-type Company Split") as described below. The Company also announced that FrontAct has entered into a business transfer agreement for medical business with MELTIN MMI on April 16, 2024. Disclosure items and details are partially omitted as the Absorption-type Company Split is a simplified absorption-type company split with a wholly-owned subsidiary of the Company.
I. The Company Split of the Frontier Business (Absorption-type Company Split)
1. Purpose of the Absorption-type Company Split
The Company operates the Frontier Business aiming to provide new solutions to resolve social issues in the field of non-pharmaceutical healthcare.
The Company established the Frontier Business Office in April 2019, and over the five years since the division's launch, the Company has expanded its development pipeline by securing new business development capabilities, intellectual properties, and business rights and has initiated the building of a platform with data business in mind, to expand its Frontier Business. Including the launch of a new medical device product in 2022, the Company expects to launch multiple products in the future, thereby entering a new phase of establishing a business foundation.
With the Absorption-type Company Split, FrontAct will further expand its network through collaboration and alliances with various business partners and academia as a company with agile business management along with realizing management decisions and business development that immediately respond to changes in customers, markets, and the environment. Under the new structure, FrontAct will pursue the possibility of incorporating capital from other companies in addition to our own capital and will focus on a sense of speed and profitability more than ever, thereby aiming to build a solid position in the business field.
The name "FrontAct" represents the FrontAct's aspiration to create innovation through cutting-edge technology and to take on (Action) new challenges (Front) that transcend the realm of pharmaceuticals. Unbound by conventional healthcare concepts, it aims to provide an innovative solution ecosystem to realize diverse lifestyles of people.
1
2. Outline of the Absorption-type Company Split (1) Schedule
Resolution of the Absorption-type Company Split by the Board of Directors
Agreement date of the Absorption-type Company Split
Effective date of the Absorption-type
Company Split
The Absorption-type Company Split shall be implemented without obtaining the
approval thereof by a resolution of a shareholders' meeting, as it is a simplified company split as stipulated in Article 784, Paragraph 2 of the Companies Act of Japan.

Bidoum67

12 mai 2024 •14:16

C'est qui frontact ? 

M7674927

12 mai 2024 •14:23

QUOI ????

M6115212

12 mai 2024 •14:54

The Company operates the Frontier Business aiming to provide new solutions to resolve social issues in the field of non-pharmaceutical healthcare

donc on n'en n'a rien à cirer !

Alfff

12 mai 2024 •17:37

Merci pas68 pour la veille incessante 😉

craftum

12 mai 2024 •17:59

j'allais l'inscrire  ! j

Dewik

12 mai 2024 •18:26

concrètement en quoi cette info influe sur Poxel  ? 

jacUse

12 mai 2024 •18:54

Encore merci Pas pour toutes ces années à lire tes découvertes.

J'ai l'intime conviction que nous abordons la dernière ligne droite.

belden

12 mai 2024 •23:08

Et en gros en quoi ça nous interresse ?🤓

pas68

13 mai 2024 •07:27

Bonjour,
Je présente toutes mes excuses à, chacun  / chacune, pour avoir, en effet, poster cette information, qui semble n'avoir aucun lien avec Poxel.
Merci à Alfff et JacUse.
Bonne journée. 
Cordialement.

pas68

13 mai 2024 •07:43

... excuses à chacun / chacune, pour avoir, en effet, posté...

loyaltou

13 mai 2024 •07:48

Bonjour Pas !
L'info en question est juste et je la connaissais, mais elle n'a, en effet, pas de lien avec ce qui nous occupe.
La question ce matin qui me préoccupe est celle de l'AMM en Chine, fake ou pas : je ne sais pas.
Sinon, je peux déjà vous donner en cumulé les ventes de Sumitomo sur les 4 derniers exercices : 4,9 B de yens
Sérieusement, je sens que Sumitomo va se débrouiller pour présenter un T4 ne nous permettant pas d'atteindre le premier palier de ventes.
Bien entendu, j'espère me tromper lourdement ....

BCF64

13 mai 2024 •10:33

Ça fait pas +150% alors

belden

13 mai 2024 •10:50

loyaltou  je crains aussi cette hypothèse 
Sdp joue vraiment un double jeu 

pre00529

13 mai 2024 •11:31

vouscroyez vraiment que l'on peut cacher des chiffres (des japonais malhonnetes ca n'existe pas en plus )et que Poxel n'a pas mis des contraintes 
vous etes des bisounours ou des pessimistes inquiets !

M4772

13 mai 2024 •11:39

DSP joue au billard à 4 bandes …poxel Sumi KGaA roivant …..je rêve qu il soit pris la main dans le sac ….le 065 et un partenariat qui n est as a exclure …la toile tissée se déchire et la ils se retrouvent le bec dans l’eau